ArticleOpen access journal of contraception2026
Metabolic and Weight Observations in Four Women Using Triphasic Norgestimate/Ethinylestradiol: A Six-month Descriptive Case Series.
Article in Open access journal of contraception, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triphasic combined oral contraceptives (COCs) containing norgestimate and ethinylestradiol are established therapeutic options. Previous studies and reviews have described their metabolic profile, but contemporary routine-practice descriptions remain limited. This report was not designed to test efficacy or to generate population-level evidence. Objective: To describe short-term changes in selected metabolic and clinical parameters over six months in four women using a triphasic norgestimate/35 µg ethinylestradiol COC. Patients and methods: This retrospective descriptive case series included four women of reproductive age, without known metabolic disorders, who initiated triphasic norgestimate/35 µg ethinylestradiol in routine clinical practice and had complete records at baseline, 3 months, and 6 months. Fasting glucose, triglycerides, total cholesterol, LDL/HDL ratio, blood pressure, and body weight were extracted from clinical records. Results are summarized descriptively as medians with ranges and patient-level changes. No inferential analyses were planned or performed. Results: Fasting glycaemia remained within the physiological range in all four patients at each time point. Median triglycerides increased from 98 mg/dL at baseline to 123 mg/dL at 3 months and decreased to 88 mg/dL at 6 months; one patient had a value of 151 mg/dL at 3 months. Median total cholesterol increased from 173 mg/dL at baseline to 195.5 mg/dL at 6 months, with two patients above 200 mg/dL at 6 months. LDL/HDL ratios remained below 2 at 6 months, although individual changes were heterogeneous. Body weight showed small individual fluctuations from baseline to 6 months (-2 to +1 kg). Conclusion: This four-patient retrospective case series provides descriptive short-term observations only. The findings should not be interpreted as evidence of metabolic efficacy, safety, or generalizability. They are hypothesis-generating and require evaluation in larger prospective studies with standardized follow-up and assessment of potential confounders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.